AR003957A1 - PHARMACEUTICAL COMPOSITION TO TREAT A MAMMAL PATIENT SUFFERING FROM A PROGRESSIVE CHRONIC VASCULAR DISEASE (CPVD) - Google Patents

PHARMACEUTICAL COMPOSITION TO TREAT A MAMMAL PATIENT SUFFERING FROM A PROGRESSIVE CHRONIC VASCULAR DISEASE (CPVD)

Info

Publication number
AR003957A1
AR003957A1 ARP960102973A AR10297396A AR003957A1 AR 003957 A1 AR003957 A1 AR 003957A1 AR P960102973 A ARP960102973 A AR P960102973A AR 10297396 A AR10297396 A AR 10297396A AR 003957 A1 AR003957 A1 AR 003957A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
cpvd
vascular disease
patient suffering
treat
Prior art date
Application number
ARP960102973A
Other languages
Spanish (es)
Original Assignee
Baker Norton Pharma
Los Estados Unidos De America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/478,347 external-priority patent/US5643892A/en
Application filed by Baker Norton Pharma, Los Estados Unidos De America filed Critical Baker Norton Pharma
Publication of AR003957A1 publication Critical patent/AR003957A1/en

Links

Abstract

Una composición farmacéutica útil para ser aplicada en un método de tratamiento de un paciente mamífero que padece una enfermedad vascularprogresiva crónica (CPVD) caracterizada por cicatrices y/o fibrosis, con el objeto de detener supro greso y causar la resolución de las lesionesexistentes. De acuerdo a dicho método, se le administra al paciente la composicion farmacéutica novedosa que contiene una cantidad efectiva depentosan polisulfato (PPS) o de una salfarmacéuticamen te aceptable del mismo. Se prefiere la vía oral de administración, oscilando la dosis diaria total dePPS o sal de PPS aproximadamente entre 50 y 1200 mg por día.A pharmaceutical composition useful to be applied in a method of treatment of a mammalian patient suffering from a chronic progressive vascular disease (CPVD) characterized by scarring and / or fibrosis, in order to stop its progression and cause the resolution of existing lesions. According to said method, the novel pharmaceutical composition containing an effective amount of pentosan polysulfate (PPS) or a pharmaceutically acceptable drug thereof is administered to the patient. The oral route of administration is preferred, with the total daily dose of PPS or PPS salt ranging from about 50 to 1200 mg per day.

ARP960102973A 1995-06-07 1996-06-06 PHARMACEUTICAL COMPOSITION TO TREAT A MAMMAL PATIENT SUFFERING FROM A PROGRESSIVE CHRONIC VASCULAR DISEASE (CPVD) AR003957A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/478,347 US5643892A (en) 1995-06-07 1995-06-07 Method of treating chronic progressive vascular diseases

Publications (1)

Publication Number Publication Date
AR003957A1 true AR003957A1 (en) 1998-09-30

Family

ID=23899571

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960102973A AR003957A1 (en) 1995-06-07 1996-06-06 PHARMACEUTICAL COMPOSITION TO TREAT A MAMMAL PATIENT SUFFERING FROM A PROGRESSIVE CHRONIC VASCULAR DISEASE (CPVD)

Country Status (7)

Country Link
AR (1) AR003957A1 (en)
AT (1) ATE235908T1 (en)
DE (1) DE69627137T2 (en)
DK (1) DK0809505T3 (en)
HK (1) HK1005497A1 (en)
PT (1) PT809505E (en)
RU (1) RU2196589C2 (en)

Also Published As

Publication number Publication date
RU2196589C2 (en) 2003-01-20
PT809505E (en) 2003-08-29
DK0809505T3 (en) 2003-07-07
DE69627137D1 (en) 2003-05-08
ATE235908T1 (en) 2003-04-15
DE69627137T2 (en) 2003-12-04
HK1005497A1 (en) 1999-01-15

Similar Documents

Publication Publication Date Title
US6713463B2 (en) Methods and compositions for treating and preventing mucositis
ES2170069T3 (en) 1-ALFA-HYDROXIPREVITAMINE D FOR ORAL ADMINISTRATION.
ES2188782T3 (en) PHARMACEUTICAL FORMULATIONS CONTAINING DARIFENACINE.
JP3623962B2 (en) Pharmaceutical composition for intranasal administration of hydroxocobalamin
IT1245761B (en) PHARMACEUTICAL FORMULATIONS CONTAINING GLYCOSAMINOGLICANS ABSORBABLE ORALLY.
IT1270594B (en) CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN
DE3789239T2 (en) Pharmaceutical composition containing interferon for buccal administration.
RU94046316A (en) Use of high effective phosphonates for preparing medicinal agents for osteoporosis treatment
ES2162615T3 (en) METHOD TO TREAT OR PREVENT TYPE 1 DIABETES THROUGH ORAL INSULIN ADMINISTRATION.
EA200000468A1 (en) THERAPEUTIC COMPOSITION FOR THE ADMINISTRATION OF TOLTERODINE WITH CONTROLLED DELIVERY
EP0296236A1 (en) Nasal delivery of caffeine
KR930007441A (en) medicine
EP0682521A4 (en) Method of treating damaged mucosal and epithelial tissues with misoprostol.
KR920703041A (en) Ingredients and methods used to treat inflammatory or allergic diseases with pain
KR970025615A (en) Cancer metastasis inhibitor
ES2115571T3 (en) USE OF PENTOSANA POLISULFATE FOR THE RESOLUTION OF SCARS IN CHRONIC PROGRESSIVE VASCULAR DISEASES.
MX9205568A (en) PHARMACEUTICAL COMPOSITION CONTAINING AMOUNTS OF 5-AMINO-1BETA-D-RIBOFURANOSIL-IMIDAZOLE-4-CARBOXAMIDE.
AR035946A1 (en) PHARMACEUTICAL COMPOSITIONS TO USE IN THE TREATMENT OF DISORDERS IN WOMEN PERIMENOPAUSIC, MENOPAUSIC OR POSMENOPAUSIC, AND USES OF SUCH COMPOSITIONS FOR THE PREPARATION OF MEDICINES
IT1244636B (en) USE OF ACETYL L-CARNITINE IN THERAPEUTIC TREATMENT OF COMA AND PHARMACEUTICAL COMPOSITIONS USEFUL IN SUCH TREATMENT.
KR890006227A (en) Phenol-containing antitussive liquid composition
AR008559A1 (en) USE OF PENTOSANPOLISULFATE (PPS) OR OF A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
AR003957A1 (en) PHARMACEUTICAL COMPOSITION TO TREAT A MAMMAL PATIENT SUFFERING FROM A PROGRESSIVE CHRONIC VASCULAR DISEASE (CPVD)
KR970005283A (en) Use of sertraline to treat patients after myocardial infarction
RU2002129298A (en) APPLICATION OF GALANTAMINE FOR THE TREATMENT OF PSYCHONEUROLOGICAL BEHAVIOR ASSOCIATED WITH ALZHEIMER'S DISEASE
RU2003100081A (en) METHODS AND COMPOSITIONS IN WHICH SULODEXIDE IS USED FOR THE TREATMENT OF DIABETIC NEPHROPATHY

Legal Events

Date Code Title Description
FC Refusal